PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 62 filers reported holding PRELUDE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,298 | -32.3% | 1,066,858 | -1.4% | 0.00% | -100.0% |
| Q2 2023 | $4,871 | +200.3% | 1,082,248 | +280.6% | 0.00% | – |
| Q1 2023 | $1,622 | -10.7% | 284,362 | -5.4% | 0.00% | – |
| Q4 2022 | $1,816 | -99.9% | 300,677 | -4.0% | 0.00% | – |
| Q3 2022 | $2,071,000 | +29.1% | 313,165 | +1.9% | 0.00% | – |
| Q2 2022 | $1,604,000 | -28.0% | 307,353 | -4.8% | 0.00% | – |
| Q1 2022 | $2,229,000 | -41.2% | 322,988 | +6.1% | 0.00% | – |
| Q4 2021 | $3,789,000 | -69.3% | 304,332 | -23.0% | 0.00% | -100.0% |
| Q3 2021 | $12,352,000 | +7.6% | 395,276 | -1.4% | 0.00% | 0.0% |
| Q2 2021 | $11,475,000 | -37.4% | 400,802 | -5.2% | 0.00% | -50.0% |
| Q1 2021 | $18,328,000 | -33.9% | 422,991 | +9.1% | 0.00% | -33.3% |
| Q4 2020 | $27,739,000 | +130.2% | 387,680 | -3.1% | 0.00% | +200.0% |
| Q3 2020 | $12,052,000 | – | 400,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $287,436,000 | 2.91% |
| Baker Brothers Advisors | 10,123,824 | $289,845,000 | 1.27% |
| Logos Global Management LP | 400,000 | $11,452,000 | 0.96% |
| Rock Springs Capital Management LP | 382,359 | $10,947,000 | 0.22% |
| HHLR ADVISORS, LTD. | 583,333 | $16,701,000 | 0.17% |
| Virtus ETF Advisers LLC | 6,622 | $190,000 | 0.08% |
| Jump Financial, LLC | 13,700 | $392,000 | 0.04% |
| ARS Investment Partners, LLC | 7,400 | $212,000 | 0.02% |
| FEDERATED HERMES, INC. | 336,100 | $9,623,000 | 0.02% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 1,287,735 | $36,867,853,000 | 0.02% |